Related Experiment Video
Updated: Sep 30, 2025
09:19
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
8.8K
Functional Ex Vivo Tissue-Based Chemotherapy Sensitivity Testing for Breast Cancer
Marjolijn M Ladan1,2, Titia G Meijer1,2, Nicole S Verkaik1,2
1Department of Molecular Genetics, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands.
Cancers
|March 10, 2022
Summary
Researchers developed new ex vivo assays to test breast cancer (BC) sensitivity to chemotherapy drugs like cisplatin and docetaxel. This could help predict treatment response and personalize BC care.
Area of Science:
- Oncology
- Translational Research
- Chemotherapy Sensitivity Assays
Background:
- Chemotherapy is a cornerstone of breast cancer (BC) treatment.
- A significant portion of BC tumors exhibit resistance to standard chemotherapy.
- Lack of predictive biomarkers hinders personalized treatment strategies.
Purpose of the Study:
- To develop ex vivo sensitivity assays for BC.
- To assess sensitivity to platinum derivatives (cisplatin) and taxanes (docetaxel).
- To utilize organotypic BC tissue slices for drug response evaluation.
Main Methods:
- Established ex vivo cisplatin sensitivity assays using organotypic tissue slices from primary BCs and metastatic biopsies.
- Developed an ex vivo docetaxel sensitivity assay using primary BC tissue slices.
- Assessed cisplatin sensitivity via morphology, proliferation, and apoptosis; docetaxel sensitivity via mitotic index.
Main Results:
- Successfully developed and validated ex vivo assays for cisplatin and docetaxel sensitivity in BC.
- Proposed a scoring system to differentiate sensitive from resistant tumors based on assay readouts.
- Demonstrated assay feasibility on biopsy-sized specimens (75% success rate for cisplatin assay).
Conclusions:
- Developed functional ex vivo assays for predicting BC response to cisplatin and docetaxel.
- Adapted assays for biopsy specimens, paving the way for clinical correlation.
- These assays represent a step towards personalized chemotherapy selection in breast cancer.
